Notice NOT-OD-25-095 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-094 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-093 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-092 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-091 from the NIH Guide for Grants and Contracts

Notice NOT-AA-25-017 from the NIH Guide for Grants and Contracts

Notice NOT-AA-25-018 from the NIH Guide for Grants and Contracts

Notice NOT-MD-25-009 from the NIH Guide for Grants and Contracts

Notice NOT-MD-25-010 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-26-002 from the NIH Guide for Grants and Contracts. This is a non-competitive funding opportunity intended to fund a single award. The National Institute on Aging is announcing its intent to issue a single source cooperative agreement award to Indiana University Indianapolis for the National Centralized Repository for Alzheimer's Disease and Related Dementias.

Notice NOT-GM-25-020 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-OD-25-008 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) aims to support new biomedical, behavioral, and social science investigators who are in the early stages of establishing independent careers in tobacco regulatory research. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies, secondary analysis of existing data, small, self-contained research projects, development of research methodology, and development of new research technology. Applicants are encouraged to conduct projects that ultimately have the potential to inform regulations on tobacco product manufacturing, distribution, and marketing. Research projects must address one or more High-Priority Research Topic(s) related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP) as mandated by the Family Smoking Prevention and Tobacco Control Act (FSPTCA), Public Law 111-31. The awards under this NOFO will be administered by NIH using funds made available through FDA CTP and the FSPTCA. Research results from this NOFO are expected to generate findings and data directly relevant to informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

Notice NOT-DE-26-002 from the NIH Guide for Grants and Contracts

Notice NOT-HL-25-028 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-437 from the NIH Guide for Grants and Contracts. The purpose of this Program Announcement with Special Receipt, Referral, and/or Review Considerations (PAR) is to solicit applications to access limited identifiable data or biospecimens from the ECHO Cohort to study high-priority areas of maternal and child health.

Notice NOT-OD-25-127 from the NIH Guide for Grants and Contracts

Notice NOT-ES-25-005 from the NIH Guide for Grants and Contracts

Notice NOT-MH-25-215 from the NIH Guide for Grants and Contracts

Notice NOT-OD-25-125 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-25-383 from the NIH Guide for Grants and Contracts. The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.